Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Status:
Completed
Trial end date:
2017-08-27
Target enrollment:
Participant gender:
Summary
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging,
and measurement of response to treatment in patients with somatostatin receptor positive
tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care
which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high
resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in
diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those
patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as
anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used
to measure response to treatment. These studies will be obtained with the long term goal of
submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and
children.